Randomized phase II study of Bevacizumab versus Bevacizumab plus Lomustine in patients with recurrent Glioblastoma: the BELOB trial.
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2017
At a glance
- Drugs Bevacizumab (Primary) ; Lomustine
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms BELOB
- 27 Jun 2017 Converging evidence from 5 seperate phase II trials (NCT00035656, NCT00345163, NCT00704288, NCT00369590 and NTR1929) results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 04 Jun 2015 Results of side study (n= 141) have been published in the British Journal of Cancer.
- 11 Apr 2013 Planned number of patients changed from 86 to 144 as reported by Netherlands Trial Register record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History